Q2 2018 13F Holders as of 30 Jun 2018
-
Type / Class
-
Equity / Common Stock, par value $0.001 per share
-
Shares outstanding
-
54.8M
-
Number of holders
-
118
-
Total 13F shares, excl. options
-
18.6M
-
Shares change
-
+1.15M
-
Total reported value, excl. options
-
$357M
-
Value change
-
+$23.5M
-
Put/Call ratio
-
0.96
-
Number of buys
-
57
-
Number of sells
-
-46
-
Price
-
$19.15
Significant Holders of Cara Therapeutics, Inc. - Common Stock, par value $0.001 per share (CARA) as of Q2 2018
151 filings reported holding CARA - Cara Therapeutics, Inc. - Common Stock, par value $0.001 per share as of Q2 2018.
Cara Therapeutics, Inc. - Common Stock, par value $0.001 per share (CARA) has 118 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 18.6M shares
of 54.8M outstanding shares and own 33.99% of the company stock.
Largest 10 shareholders include RHO CAPITAL PARTNERS INC (3.57M shares), BlackRock Inc. (2.24M shares), STATE STREET CORP (1.72M shares), VANGUARD GROUP INC (1.25M shares), Chescapmanager LLC (1.16M shares), DISCIPLINED GROWTH INVESTORS INC /MN (858K shares), FMR LLC (692K shares), Carmignac Gestion (604K shares), FIRST MANHATTAN CO (557K shares), and PRICE T ROWE ASSOCIATES INC /MD/ (472K shares).
This table shows the top 118 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.